Literature DB >> 12842324

In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.

D M Livermore1, S Mushtaq, D James, N Potz, R A Walker, A Charlett, F Warburton, A P Johnson, M Warner, C J Henwood.   

Abstract

Piperacillin/tazobactam is used for empirical therapy of severe and complex infections. We assessed its activity, 9 years after launch, against consecutive, clinically significant isolates from in-patients in UK and Ireland. Standardised disc susceptibility tests were performed on 5031 isolates at 28 hospitals. For quality assurance purposes, 5% of these isolates were collected centrally for MIC tests, as were those with exceptional resistances. Compared with a similar pre-launch survey in 1991, there were major increases in the proportions of Staphylococcus aureus, Pseudomonas aeruginosa, beta-haemolytic streptococci and Enterococcus faecium isolates collected, balanced by decreases in Escherichia coli, Proteus mirabilis and coagulase-negative staphylococci. These changes in species prevalence mostly favoured organisms with inherent resistance(s) or-in the case of S. aureus-reflected the massive increase of MRSA, up from 0.7% of all isolates in 1991 to 14.8% in 2001. Based on the disc tests, piperacillin/tazobactam retained activity against 87% of Enterobacteriaceae isolates, 95% of P. aeruginosa, 99% of streptococci and 96% of Enterococcus faecalis. Resistance nevertheless had increased since 1991 in E. coli from 4 to 10%, Klebsiella spp. (5 to 21%) and in AmpC-inducible Enterobacteriaceae (17 to 23%), though not in P. mirabilis or P. aeruginosa. MIC tests confirmed most of the piperacillin/tazobactam resistance found by disc tests in Enterobacter spp., but indicated susceptibility for about half of the E. coli isolates recorded as resistant in disc tests. This situation might be remedied by reducing the zone breakpoint, but this would increase the "false susceptible" rate unacceptably. Thus, if disc tests suggest that an isolate is marginally resistant to piperacillin/tazobactam and the drug is sought as therapy, it is recommended that MIC be determined with, e.g., an Etest.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842324     DOI: 10.1016/s0924-8579(03)00108-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  Prospective evaluating the appropriate use of piperacillin /tazobactam in cardiac center of a tertiary care hospital.

Authors:  Sanaa Saeed Mekdad; Leenah AlSayed
Journal:  J Cardiothorac Surg       Date:  2020-05-01       Impact factor: 1.637

2.  Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy.

Authors:  Graeme N Forrest; Mary-Claire Roghmann; Latoya S Toombs; Jennifer K Johnson; Elizabeth Weekes; Durry P Lincalis; Richard A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

Review 3.  Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance.

Authors:  L R Peterson
Journal:  Clin Microbiol Infect       Date:  2005-10       Impact factor: 8.067

4.  Genomic surveillance of Escherichia coli ST131 identifies local expansion and serial replacement of subclones.

Authors:  Catherine Ludden; Arun Gonzales Decano; Dorota Jamrozy; Derek Pickard; Dearbhaile Morris; Julian Parkhill; Sharon J Peacock; Martin Cormican; Tim Downing
Journal:  Microb Genom       Date:  2020-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.